Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edwards scraps AAA program

This article was originally published in The Gray Sheet

Executive Summary

Edwards Lifesciences' inability to find a buyer for its LifePath aortic aneurysm endovascular graft system will lead to termination of the program, the company says. The only firms with endovascular surgery sales forces capable of supporting LifePath already offer AAA grafts or are developing them, Edwards explains. The company announced its intention to exit the AAA business in December (1"The Gray Sheet" Dec. 15, 2003, p. 7). European sales will end in June. Edwards says it will complete patient follow-up for a U.S. study which closed enrollment in January...

You may also be interested in...



Selling AAA in Europe

Edwards Lifesciences will distribute Endologix' PowerLink abdominal aortic aneurysm stent graft in Belgium, France, Germany and the UK. PowerLink received CE mark in 1999. A PMA is pending at FDA, and the firm expects approval during the second half of the year. Endologix plans to create a direct sales force for U.S. commercialization. Edwards recently abandoned its LifePath AAA program after unsuccessfully seeking a buyer (1"The Gray Sheet" April 12, 2004, In Brief)...

Edwards Follows Guidant’s Exit From AAA Market, Seeks Lifepath Acquirer

Edwards Lifesciences' decision to suspend its Lifepath endovascular graft program accompanies a realignment of R&D priorities to cope with the rapidly maturing AAA market

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
UsernamePublicRestriction

Register

MT020044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel